Milestone Mojo release reveals a systems programming language with precise control over memory, strong types, GPU programming ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

Wall Street Prep (WSP) today announced that Bogdan Tudose has joined the firm as Head of AI and Data Science. In this newly created role, Tudose will lead WSP's AI strategy across its training ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Global ...

1:24 Health Canada approves generic semaglutide for adults with type 2 diabetes Canada is the first G7 country to authorize generic semaglutide. There are now seven other submissions currently under ...

Apotex Inc., Canada’s largest drug maker, has won Health Canada approval to sell a generic form of the blockbuster Ozempic. The Toronto-based company is the second manufacturer to get an approval, ...

Canada is the first G7 country to approve a generic version of semaglutide injection — an alternative to the name-brand Ozempic — prescribed to treat type-2 diabetes and to aid in weight loss. The ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Health Canada ‌ ...

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...